Cargando…

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy

OBJECTIVE: The purpose of this study was to initially investigate the effect of previous antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients with advanced or metastatic lung cancer (LC). METHODS: We retrospectively collected the clinical data of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suo, Jiaojiao, Sun, Yu, Fu, Yan, Xiu, Weigang, Zhang, Xuanwei, Wang, Yan, Zhu, Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732369/ https://www.ncbi.nlm.nih.gov/pubmed/35004313 http://dx.doi.org/10.3389/fonc.2021.788837

Ejemplares similares

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Suo, Jiaojiao, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
por: Chen, Ling, et al.
Publicado: (2023)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
por: Li, Jing, et al.
Publicado: (2021)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
por: Zheng, Hui, et al.
Publicado: (2021)

The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports
por: Yang, Song, et al.
Publicado: (2021)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
por: Xu, Fei, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
por: Fan, YH, et al.
Publicado: (2022)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases
por: Qu, Hui, et al.
Publicado: (2023)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
por: Hao, Yan-Yan, et al.
Publicado: (2021)

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
por: Ding, Jianghua, et al.
Publicado: (2023)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Gan, Yuying, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
por: Feng, Jin-Kai, et al.
Publicado: (2022)

Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy
por: Tian, Jin, et al.
Publicado: (2023)

Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors
por: Indraccolo, Stefano, et al.
Publicado: (2016)

A Short-Term Efficacy of Anlotinib in the Treatment of Refractory Nasopharyngeal Inverted Papilloma: A Case Report
por: Yang, Pan, et al.
Publicado: (2021)

Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report
por: Zhang, Zibo, et al.
Publicado: (2022)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
por: Jin, Nan, et al.
Publicado: (2022)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
por: Yue, Yanhua, et al.
Publicado: (2022)

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
por: Gu, Yuanyuan, et al.
Publicado: (2022)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0gcksh0f7r7p7c5f8vketd4fa2